BillionToOne (BLLN) reported $96.05 million in revenue for the quarter ended December 2025, representing no change year over year. EPS of $0.11 for the same period compares to $0 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $85.85 million, representing a surprise of +11.89%. The company delivered an EPS surprise of +69.23%, with the consensus EPS estimate being $0.07.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how BillionToOne performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Total tests delivered: 170,000 compared to the 172,644 average estimate based on two analysts.
- Overall ASP: $561.00 versus the two-analyst average estimate of $484.19.
- Revenue- Prenatal: $86.1 million versus the three-analyst average estimate of $75.37 million.
- Revenue- Oncology: $9.1 million compared to the $8.82 million average estimate based on three analysts.
- Revenue- Clinical Trial Support and Other Services: $0.8 million compared to the $1.28 million average estimate based on three analysts.
View all Key Company Metrics for BillionToOne here>>>
Shares of BillionToOne have returned +0.5% over the past month versus the Zacks S&P 500 composite's -1.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BillionToOne, Inc. (BLLN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
